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Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in
node-positive breast cancer
D.W. Miles, L.C. Happerfield, P. Smith, R. Gillibrand, L.G. Bobrow, W.M. Gregory &
R.D. Rubens
ICRF Clinical Oncology Unit, Guy's Hospital, St Thomas' Street, London SE] 9RT, UK.
Summary Sialyl-Tn (STn) is a carcinoma-associated carbohydrate determinant expressed on cancer-associated
mucins and has the structure NANAa(2-6)aGalNAc. Expression of STn in colon and ovarian cancer is
associated with a poor prognosis independent of tumour grade, stage or histological type. We have examined
237 cases of primary breast cancer for expression of this antigen using the antibody HB-STn (Dako). The
frequency of STn expression was 31% in the whole group, 36% in the node-negative and 28% in the
node-positive group. Survival was lower, but not significantly so, in the STn-positive group (P = 0.07), but this
effect was highly significant for patients with node-positive disease (P<0.002), the curves for node-negative
disease being coincident (P= 0.31). In node-positive disease the effect was limited to those receiving adjuvant
chemotherapy (P = 0.001). In a multivariate (Cox) analysis on the whole group STn staining, combined with
adjuvant chemotherapy, showed a highly significant correlation with survival. In STn-negative cases, adjuvant
chemotherapy improved survival (relative risk 2.3, 95% confidence intervals 1.4-3.9), whereas adjuvant
chemotherapy did not influence survival in patients which expressed STn (relative risk 1.1, 95% confidence
intervals 0.6-2.2). Thus, by either direct or indirect mechanisms, STn positivity appears to be a marker of
resistance to adjuvant chemotherapy.
Abnormal glycosylation patterns have been recognised as a
feature of carcinoma-associated mucins (Hakomori, 1985).
Expression of blood group-related carbohydrate antigens
demonstrated by lectin binding (Fenlon et al., 1987; Leathem
& Brooks, 1987) and monoclonal antibodies (Narita et al.,
1993) has been shown to be of prognostic importance in
primary breast cancer. One potential mechanism to explain
this finding is that blood group-related antigens such as
sialyl-Lea and sialyl Lex are known to be ligands for the
endothelial cell adhesion molecule ELAM-l/E-selectin (Lowe
et al., 1990; Takada et al., 1991), which may therefore result
in an increase in the metastatic potential of malignant cells
expressing these antigens.
Sialyl-Tn [a(2-6)-N-acetylgalactosamine, STn] is a core
region carbohydrate antigen of tumour-associated mucin
(Kjeldsen et al., 1988) formed by the premature 2-6 sialation
of N-acetylgalactosamine (Nakasaki et al., 1989). STn expres-
sion has been studied in several tumour types and found to
be of prognostic significance in colonic (Itzkowitz et al.,
1990) and gastric carcinoma (Chun Ma et al., 1993). Cir-
culating antigen has been detected in gastrointestinal and
ovarian malignancies, and raised levels have also been shown
to be associated with a poor prognosis (Motoo et al., 1991;
Kobayashi et al., 1992).
The incidence of expression of STn in primary breast
cancer has been reported previously and is less than that
observed in gastrointestinal and ovarian malignancies
(Yonezawa et al., 1992). In this study we have examined the
prognostic significance of STn expression in primary breast
cancer.
Patients and methods
Patients
Case records of 237 patients with primary operable breast
cancer were reviewed. All patients had a total mastectomy
and axillary clearance or a conservation technique compris-
ing excision biopsy and axillary clearance followed by iridium
implant and external beam radiotherapy as primary treat-
ment. As part of a controlled trial testing adjuvant
chemotherapy in patients with node-positive disease, 78 of
148 patients randomised received chemotherapy post-
operatively. Chemotherapy (CMF) was cyclophosphamide
80 mg m-2 orally on days 1-14, methotrexate 32 mg m-2
intravenously on days 1 and 8 of each cycle and fluorouracil
480mgm2 intravenously on days I and 8 of each cycle.
Chemotherapy was repeated every 28 days for 12 cycles. The
results of this trial have been reported previously (Howell et
al., 1984). During this period patients with node-negative
disease were not routinely given chemotherapy, although one
patient in this group did receive adjuvant CMF. Tumour size
measured clinically was recorded in 234 cases. Steroid hor-
mone receptor status was determined using a dextran-coated
ligand binding assay (King et al., 1979) with a value of
> 10 fmolmg-' cytosol protein taken as positive. Data on
oestrogen receptor (ER) status was available on 218 tumours
and on progesterone receptors (PgR) on 213 tumours. The
histological type of all tumours was documented at diagnosis
and infiltrating ductal tumours were graded according to the
criteria of Bloom and Richardson (1957).
Immunohistochemistry
Staining for STn was assessed on 4pm sections cut from
formalin-fixed, paraffin-embedded tissue. Sections were
incubated for 30 min at room temperature with the antibody
HB-STn (Dako) raised against ovine submaxillary mucin at a
dilution of 1 in 100. Sections were then treated with
biotinylated rabbit anit-mouse immunoglobulin followed by
avidin-biotin complex. Peroxidase activity was demonstrated
using diaminobenzidine solution and nuclei were counter-
stained with Mayer's haematoxylin. Any case in which
invasive carcinoma cells expressed STn was regarded as
positive.
Statistical analysis
Relationships between variables were examined using the
chi-squared and Mann-Whitney tests. Relapse-free and
overall survival were calculated using the method of Kaplan
and Meier (Peto et al., 1977), and differences between curves
were analysed by the log-rank test. Multivariate analysis was
by Cox's proportional hazards model (Cox, 1972).
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Results
STn expression was noted in 74 of 237 (31%) tumours
examined (Figure 1). STn staining was usually coarsely
granular and showed pan-cytoplasmic distribution.
Occasionally when luminal differentiation was present the
staining was located along the luminal surface. In most cases
showing STn expression, staining was seen in 25-75% of
tumour cells, but in some cases staining of less than 25% of
cells was observed when positive cells were either scattered
singly throughout sheets of negatively stained tumour cells or
were present in small foci. The relationship between STn
staining and other tumour characteristics is shown in Table I,
none being statistically significant.
Although patients with STn-positive tumours had a lower
survival, this was not significant (P = 0.07, Figure 2). The
influence of STn positivity on survival was then examined
within subgroups defined by nodal status. STn positivity did
not influence survival in patients with node-negative breast
cancer (P = 0.31, Figure 3) but in the node-positive group
those patients which were also STn positive had a shorter
survival than those with STn-negative tumours (P<0.001,
Figure 3). STn positivity was not ofprognostic significance in
patients with node-positive disease who did not receive
adjuvant chemotherapy (P = 0.24, Figure 4), but was in those
so treated (P = 0.001, Figure 4). Established prognostic fac-
tors were well balanced in the two arms of the adjuvant
chemotherapy study (data previously published). There was
no imbalance of prognostic factors between STn-positive
and-negative patients who received adjuvant chemo-
therapy.
In univariate analyses, nodal status was the most powerful
predictor of relapse-free (P<0.0001, Table II) and overall
survival (P<0.0001. Table III). Multivariate analyses were
performed to assess the independence of the prognostic in-
formation given by STn staining interacting with adjuvant
chemotherapy. Although nodal status remained the most
powerful predictor of relapse-free survival, the interaction of
adjuvant chemotherapy and STn negativity was a significant
independent prognostic variable for survival (x2 = 10.15,
Figure 1 Infiltrating ductal carcinoma of breast which shows
positive staining with the anti-STn antibody in the majority of
tumour cells. Both cytoplasmic and membrane expression is pre-
sent in this section. Bar = 100 lum.
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Figure 2 Overall survival by STn staining. (a) STn negative. (b)
STn positive.
Table I Presentation characteristics
STn -ve STn + ve
Factor (n = 163) (n = 74) P-value
Age
Mean 50 53
Range 24-84 28-74
Tumour size
Median (cm) 3 3 O.51a
Nodal status
Negative 58 (36%) 31 (42%)
1-3 nodes positive 56 (34%) 20 (27%) | b
4-9 nodes positive 24 (15%) 10 (14%) 0.66
> 10 nodes positive 25 (15%) 13 (18%) )
Menstrual status
Pre 89 (55%) 32 (43%)
Peri 20 (12%) 9 (12%) 1 0.23b
Post 53 (33%) 32 (43%)
Uncertain 1 1I
Histology
Ductal grade I 12 (7%) 1 (1%)
Ductal grade II 59 (36%) 30 (41%) 1
Ductal grade III 63 (39%) 27 (37%) 0.27b
Lobular 19 (12%) 8 (11%) 1
Other 10 (6%) 8 (10%) )
ER status
Negative 40 (26%) 24 (36%)
Positive 112 (74%) 42 (64%) .19b
Unknown 11 8 J
PgR status
Negative 58 (40%) 35 (53%)
Positive 89 (61%) 31 (47%) 0.18b
Unknown 11 8 J
aMann-Whitney. bChisquared.
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Figure 3 Overall survival by nodal status and STn staining. (a)
Node negative, STn positive (n 31). (b) Node negative, STn
negative (n = 58). (a) vs (b), x2 = 1.05, P = 0.31. (c) Node
positive, STn negative (n = 105). (d) Node positive, STn positive
(n = 43). (c) vs (d), x2 = 10.97, P<0.001.
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Figure 4 Overall survival of node-positive patients by adjuvant
treatment and STn staining: (a) STn negative, received adjuvant
chemotherapy (n = 59). (b) STn negative, no adjuvant chemo-
therapy (n = 46). (c) STn positive, no adjuvant chemotherapy
(n = 24). (d) STn positive, received adjuvant chemotherapy
(n = 14). (a) vs (d) x2 = 10.63, P= 0.001. (b) vs (c) X2= 1.4,
P=0.24.
Table II Analysis of prognostic factors for relapse-free survival
Univariate Multivariate
Variable X2 P-value X2 P-value
Nodal status 39.5 <0.0001 51.13 <0.0001
Adjuvant CT/STn -ve 2.01 0.16 10.15 0.001
Histology 6.49 0.01 8.61 0.003
Tumour size (log) 8.85 0.003 6.02 0.01
Adjuvant CT 2.63 0.01 3.20 0.07
Table III Analysis of prognostic factors for overall survival
Univariate Multivariate
Variable X2 P-value x2 P-value
Nodal status 35.97 <0.0001 45.41 <0.0001
Adjuvant CT/STn -ve 2.75 0.097 11.79 0.0006
Histology 7.25 0.007 10.81 0.001
Tumour size (log) 8.91 0.003 4.75 0.03
Adjuvant CT 1.32 0.25 1.36 0.24
P = 0.0001; Table II). In terms of overall survival, adjuvant
chemotherapy and STn negativity remained an independent
prognostic factor (X2 = 11.79, P = 0.0006; Table III). Admini-
stration of adjuvant chemotherapy in patients with node-
positive disease whose tumours were STn negative was
associated with improved survival [relative risk 2.3, 95%
confidence intervals (CI) 1.4-3.9]. Conversely, the use of
adjuvant chemotherapy for node-positive and STn-positive
tumours did not improve survival (relative risk 1.1, 95% CI
0.6-2.2).
Discussion
Malignant transformation of epithelial cells is frequently
associated with altered glycosylation of cell membrane glyco-
proteins or glycolipids. In the case of 0-linked oligosac-
charides, the premature 2-6 sialation of the Tn antigen
(GalNAc) leads to accumulation of the STn antigen (Naka-
saki et al., 1989). Expression of this carcinoma-associated
antigen sialyl Tn has been shown to be a prognostic factor in
ovarian, gastric and colorectal adenocarcinomas. It has been
demonstrated that normal glycoproteins (Simon et al., 1990),
tumour-associated glycoproteins (Irimura et al., 1987) and
sialic acid residues (Dennis et al., 1982) may be involved in
cell-cell or cell-matrix interactions. It has been postulated
therefore that the association of STn expression and poor
prognosis may be due to such interactions in a manner
analogous to the interactions between ELAM-1 and the
blood group-related antigens sialyl Lewis A and sialyl Lewis
X. Cells expressing STn might therefore be expected to have
higher metastatic potential.
In this study, we have examined the effects of STn expres-
sion on prognosis in operable breast cancer. STn expression
was noted in the invasive component of primary breast
cancers in nearly one-third of cases. Expression was not
associated with other known prognostic factors. In parti-
cular, STn expression was not associated with nodal status,
which may suggest that different mechanisms are involved in
lymphatic and blood-borne dissemination. For the whole
group of patients, STn expression was of borderline prognos-
tic significance. In the subgroup of patients who were node
negative, the survival curves were coincident, whereas in the
node-positive group STn expression was associated with a
poorer prognosis. The prognostic value of STn expression
appeared to be confined to the node-positive group which
received adjuvant chemotherapy in that patients with STn-
negative tumours who received adjuvant chemotherapy had
an improved survival compared with those not so treated. By
contrast, administration of adjuvant chemotherapy to those
patients whose tumours expressed STn did not influence
survival. Thus STn positivity by either direct or indirect
mechanisms appears to be a marker of resistance to adjuvant
chemotherapy. The findings from this retrospective analysis
require corroboration and, if confirmed, would have major
implications for the selection of patients for adjuvant
chemotherapy.
Although STn positivity may reflect aberrant glycosylation
of other peptides, the function of P-glycoprotein, associated
with multidrug resistance, is not influenced by its degree of
glycosylation (Beck & Cirtain, 1982; Ling et al., 1983). Pro-
posed mechanisms of drug resistance are based largely on
unicellular characteristics involving reduced drug uptake, in-
creased drug efflux, increased drug inactivation, increased
DNA repair and altered molecular expression of drug targets
within cells. Other evidence showing that tumour cells grown
in monolayer culture may be more sensitive to cytotoxic
drugs than when grown as multicellular spheroids (Suther-
land, 1988), suggests that some forms of drug resistance
operate at a multicellular level. Altered cell-cell interactions
as a result of aberrant carbohydrate expression may be
important in mediating this type of drug resistance.STn EXPRESSION IN PRIMARY BREAST CANCER 1275
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